TOPICAL NAIL FORMULATION
The present invention relates to a topical nail formulation comprising at least one active agent (e.g., tolnaftate) and at least one nail penetration enhancer selected from the group consisting of a fatty acid, an azone derivative, and mixtures thereof. The invention also relates to the use of said topical nail formulation for the treatment of nail disorders such as onychomycosis. The invention further provides a method of enhancing the nail flux of an active agent by using a topical nail formulation containing the said penetration enhancer.
1 . A topical nail formulation comprising at least one active agent and at least one penetration enhancer selected from the group consisting of a fatty acid, an azone-related compound and mixtures thereof.
2 . The topical nail formulation defined in claim 1 , wherein the at least one active agent is selected from the group consisting of an antifungal agent, an anti-inflammatory agent, an anti-cancer agent, an antipsoriatic agent and pharmaceutically acceptable salts thereof.
3 . The topical nail formulation defined in claim 2 , wherein the antifungal agent is selected from the group consisting of ketoconazole, miconazole, bifonazole, butoconazole, clotrimazole, croconazole, eberconazole, econazole, fenticonazole, flutimazole, isoconazole, ketoconazole, lanoconazole, neticonazole, omoconazole, oxiconazole, setraconazole, sulconazole, tioconazole, fluconazole, itraconazole, terconazole, terbinafine, natrifine, amorolfine, amphotericin B, nystatin, natamaycin, flucytosine, griseofulvin, potassium iodide, butenafine, ciclopirox, ciloquinol (iodochlorhydroxyquin), haloprogin, tolnaftate, aluminum chloride, undecylenic acid, potassium permanganate, selenium sulphide, salicylic acid, zinc pyruthione, bromochlorsalicylanilide, methylrosaniline, tribromometacresol, undecylenic acid, polynoxylin, 2-(4-chlorphenoxy)-ethanol, chlorophensesin, ticlatone, sulbentine, ethyl hydroxybenzoate, dimazole, tolciclate, sulphacetamide, benzoic acid and pharmaceutically acceptable salts thereof.
4 . The topical nail formulation defined in claim 2 , wherein the antifungal agents is selected from the group consisting of econazole, terbinafine, butenafine, tolnaftate and pharmaceutically acceptable salts thereof.
5 . The topical nail formulation defined in claim 2 , wherein the antifungal agent is tolnaftate or a pharmaceutically acceptable salt thereof.
6 . The topical nail formulation defined in claim 1 , wherein the fatty acid is selected from the group consisting of alkanoic acids, capric acid, diacid, ethyloctadecanoic acid, hexanoic acid, lactic acid, lauric acid, linoelaidic acid, linoleic aid, linolenic acid, neodecanoic acid, oleic acid, palmitic acid, pelargonic acid, propionic acid, vaccenic acid and mixtures thereof.
7 . The topical nail formulation defined in claim 1 , wherein the fatty acid is oleic acid.
8 . The topical nail formulation defined in claim 1 , wherein the azone-related compound is selected from the group consisting of N-acyl-hexahydro-2-oxo-1H-azepines, N-alkyl-dihydro-1,4-oxazepine-5,7-diones, N-alkymorpholine-2,3-diones, N-alkylmorpholine-3,5-diones, azacycloalkane derivatives (-ketone, -thione), azacycloalkenone derivatives, 1-[2-(decylthio)ethyl]azacyclopentan-2-one, N-(2,2-dihydroxyethyl)dodecylamine, 1-dodecanoylhexahydro-1-H-azepine, 1-dodecyl azacycloheptan-2-one, N-dodecyl diethanolamine, N-dodecyl-hexahydro-2-thio-1H-azepine, N-dodecyl-N-(2-methoxyethyl)acetamide, N-dodecyl-N-(2-methoxyethyl)isobutyramide, N-dodecyl-piperidine-2-thione, N-dodecyl-2-piperidinone, N-dodecyl pyrrolidine-3,5-dione, N-dodecyl pyrrolidine-2-thione, N-dodecyl-2-pyrrolidone, 1-farnesylazacycloheptan-2-one, 1-farnesylazacyclopentan-2-one, 1-geranylazacycloheptan-2-one, 1-geranylazacyclopentan-2-one, hexahydro-2-oxo-azepine-1-acetic acid esters, N-(2-hydroxyethyl)-2-pyrrolidone, 1-laurylazacycloheptane, 2-(1-nonyl)-1,3-dioxolane, 1-N-octylazacyclopentan-2-one, N-(1-oxododecyl)-hexahydro-1H-azepine, N-(1-oxododecyl)-morpholines, 1-oxohydrocarbyl-substituted azacyclohexanes, N-(1-oxotetradecyl)-hexahydro-2-oxo-1H-azepine, N-(1-thiododecyl)-morpholines and mixtures thereof.
9 . The topical nail formulation defined in claim 1 , wherein the azone-related compound is 1-dodecyl azacycloheptan-2-one.
10 . The topical nail formulation defined in claim 1 , wherein the concentration of the penetration enhancer is from about 1% to about 50% by weight of the composition.
11 . The topical nail formulation defined in claim 1 , wherein the concentration of the penetration enhancer is from about 1% to about 30% by weight of the concentration.
12 . The topical nail formulation defined in claim 1 , wherein the concentration of the penetration enhancer is from about 1% to about 10% by weight of the concentration.
13 . The topical nail formulation defined in claim 1 , wherein the concentration of the penetration enhancer is from about 1% to about 5% by weight of the concentration.
14 . The topical nail formulation defined in claim 1 , further comprising at least one organic sulfoxide.
15 . The topical nail formulation defined in claim 14 , wherein the at least one organic sulfoxides is selected from the group consisting of dimethyl sulfoxide, 1-methylpropyl methyl sulfoxide, 1,1-dimethylpropyl methyl sulfoxide, 1,1-dimethylethyl methyl sulfoxide, 1-methylbutyl methyl sulfoxide, 1,1-dimethylbutyl methyl sulfoxide, 1-ethylbutyl methyl sulfoxide, 1-propylpentyl methyl sulfoxide, trimethylene sulfoxide, 1-propyltrimethylene sulfoxide, 1-butyltrimethylene sulfoxide, thiophene oxide, methyl ethyl sulfoxide, methyl ethylene sulfoxide, 2-hydroxyundecyl methyl sulfoxide, N-decylmethyl sulfoxide and mixtures thereof
16 . The topical nail formulation defined in claim 14 , wherein the at least one organic sulfoxide is dimethyl sulfoxide.
17 . A topical nail formulation comprising at least one antifungal agent and a penetration enhancer selected from oleic acid, azone and mixtures thereof.
18 . The topical formulation defined in claim 17 , wherein the antifungal agent is selected from the group consisting of azoles, allylamines, morpholines, polyenes, tetraenes, pyrimidines, thiocarbamates, sulfonamides, organic acids, hydroxides, echinocandins and pharmaceutically acceptable salts thereof.
19 . The topical formulation defined in claim 17 , wherein the antifungal agent is selected from the group consisting of econazole, terbinafine, butenafine, tolnaftate and pharmaceutically acceptable salts thereof.
20 . The topical formulation defined in claim 17 , wherein the antifungal agent is tolnaftate or a pharmaceutically acceptable salt thereof.
21 . The topical formulation defined in claim 17 , wherein the concentration of oleic acid is from about 1% to about 50%.
22 . The topical formulation defined in claim 17 , wherein the concentration of oleic acid is from about 1% to about 30%.
23 . The topical formulation defined in claim 17 , wherein the concentration of oleic acid is from about 1% to about 10%.
24 . The topical formulation defined in claim 17 , wherein the concentration of oleic acid is from about 1% to about 5%.
25 . The topical formulation defined in claim 17 , wherein the concentration of oleic acid is about 5%.
26 . The topical formulation defined in claim 17 , wherein the concentration of azone is from about 1% to about 50%.
27 . The topical formulation defined in claim 17 , wherein the concentration of azone is from about 1% to about 30%.
28 . The topical formulation defined in claim 17 , wherein the concentration of azone is from about 1% to about 10%.
29 . The topical formulation defined in claim 17 , wherein the concentration of azone is from about 1% to about 5%.
30 . The topical formulation defined in claim 17 , wherein the concentration of azone is about 5%.
31 . The topical formulation defined in claim 17 , wherein the concentration of azone is about 2%.
32 . The topical formulation defined in claim 17 , wherein the concentration of azone is about 1%.
33 . The topical formulation defined in claim 17 , further comprising at least one organic sulfoxide.
34 . The topical formulation defined in claim 33 , wherein the at least one organic sulfoxide is selected from the group consisting of dimethyl sulfoxide, 1-methylpropyl methyl sulfoxide, 1,1-dimethylpropyl methyl sulfoxide, 1,1-dimethylethyl methyl sulfoxide, 1-methylbutyl methyl sulfoxide, 1,1-dimethylbutyl methyl sulfoxide, 1-ethylbutyl methyl sulfoxide, 1-propylpentyl methyl sulfoxide, trimethylene sulfoxide, 1-propyltrimethylene sulfoxide, 1-butyltrimethylene sulfoxide, thiophene oxide, methyl ethyl sulfoxide, methyl ethylene sulfoxide, 2-hydroxyundecyl methyl sulfoxide, N-decylmethyl sulfoxide and mixtures thereof
35 . The topical formulation defined in claim 33 , wherein the at least one organic sulfoxide is dimethyl sulfoxide.
36 . A topical nail formulation comprising a penetration enhancer selected from the group consisting of a fatty acid, an azone-related compound and mixtures thereof.
37 . The topical formulation defined in claim 36 , further comprising at least one active agent.
38 . The topical formulation defined in claim 36 , wherein the fatty acid is selected from the group consisting of is selected from the group consisting of alkanoic acids, capric acid, diacid, ethyloctadecanoic acid, hexanoic acid, lactic acid, lauric acid, linoelaidic acid, linoleic aid, linolenic acid, neodecanoic acid, oleic acid, palmitic acid, pelargonic acid, propionic acid, vaccenic acid and mixtures thereof.
39 . The topical formulation defined in claim 36 , wherein the fatty acid is oleic acid.
40 . The topical formulation defined in claim 36 , wherein the azone-related compound is selected from the group consisting of N-acyl-hexahydro-2-oxo-1H-azepines, N-alkyl-dihydro-1,4-oxazepine-5,7-diones, N-alkymorpholine-2,3-diones, N-alkylmorpholine-3,5-diones, azacycloalkane derivatives (-ketone, -thione), azacycloalkenone derivatives, 1-[2-(decylthio)ethyl]azacyclopentan-2-one, N-(2,2-dihydroxyethyl)dodecylamine, 1-dodecanoylhexahydro-1-H-azepine, 1-dodecyl azacycloheptan-2-one, N-dodecyl diethanolamine, N-dodecyl-hexahydro-2-thio-1H-azepine, N-dodecyl-N-(2-methoxyethyl)acetamide, N-dodecyl-N-(2-methoxyethyl)isobutyramide, N-dodecyl-piperidine-2-thione, N-dodecyl-2-piperidinone, N-dodecyl pyrrolidine-3,5-dione, N-dodecyl pyrrolidine-2-thione, N-dodecyl-2-pyrrolidone, 1-farnesylazacycloheptan-2-one, 1-farnesylazacyclopentan-2-one, 1-geranylazacycloheptan-2-one, 1-geranylazacyclopentan-2-one, hexahydro-2-oxo-azepine-1-acetic acid esters, N-(2-hydroxyethyl)-2-pyrrolidone, 1-laurylazacycloheptane, 2-(1-nonyl)-1,3-dioxolane, 1-N-octylazacyclopentan-2-one, N-(1-oxododecyl)-hexahydro-1H-azepine, N-(1-oxododecyl)-morpholines, 1-oxohydrocarbyl-substituted azacyclohexanes, N-(1-oxotetradecyl)-hexahydro-2-oxo-1H-azepine, N-(1-thiododecyl)-morpholines and mixtures thereof.
41 . The topical formulation defined in claim 36 , wherein the azone-related compound is 1-dodecyl azacycloheptan-2-one.
42 . The topical formulation defined in any one of claims 1 through 41 , further comprising at least one pharmaceutically acceptable carrier.
43 . A topical nail formulation comprising:
(i) between about 1% to about 10% w/w azone;
(ii) between about 1% to about 25% w/w propylene glycol;
(iii) between about 1% to about 15% w/w glycerine;
(iv) between about 1% to about 25% w/w ethanol;
(v) between about 1% to about 80% w/w polyethylene glycol 300; and
(vi) at least one active agent.
44 . The topical nail formulation defined in claim 43 , wherein the at least one active agent is selected from the group consisting of an antifungal agent, an anti-inflammatory agent, an anti-cancer agent, an antipsoriatic agent and pharmaceutically acceptable salts thereof.
45 . The topical nail formulation defined in claim 43 , wherein the at least one active agent is an antifungal agent or a pharmaceutically acceptable salt thereof.
46 . The topical nail formulation defined in claim 43 , wherein the at least one active agents is selected from the group consisting of econazole, terbinafine, butenafine, tolnaftate and pharmaceutically acceptable salts thereof
47 . The topical nail formulation defined in claim 43 , wherein the at least one active agent is tolnaftate.
48 . The topical nail formulation defined in claim 43 , wherein the azone is present between about 1% to about 5% by weight of the formulation.
49 . A topical nail formulation comprising:
(i) between about 1% to about 10% w/w oleic acid;
(ii) between about 1% to about 25% w/w propylene glycol;
(iii) between about 1% to about 15% w/w glycerine;
(iv) between about 1% to about 25% w/w ethanol;
(v) between about 1% to about 80% w/w polyethylene glycol 300; and
(vi) at least one active agent.
50 . The topical nail formulation defined in claim 49 , wherein the at least one active agent is selected from the group consisting of an antifungal agent, an anti-inflammatory agent, an anti-cancer agent, an antipsoriatic agent and pharmaceutically acceptable salts thereof.
51 . The topical nail formulation defined in claim 49 , wherein the at least one active agent is an antifungal agent or a pharmaceutically acceptable salt thereof.
52 . The topical nail formulation defined in claim 49 , wherein the at least one active agent is selected from the group consisting of econazole, terbinafine, butenafine, tolnaftate and pharmaceutically acceptable salts thereof.
53 . The topical nail formulation defined in claim 49 , wherein the at least one active agent is tolnaftate or a pharmaceutically acceptable salt thereof.
54 . The topical nail formulation defined in claim 49 , wherein the oleic acid is present between about 1% to about 5% by weight of the formulation.
55 . A method of treating or ameliorating a nail condition comprising the steps of administering to a nail in need of such treatment a therapeutically effective amount of the nail formulation of claim 17 .
56 . The method defined in claim 55 , wherein the nail condition is onychomycosis.
57 . A method for enhancing the nail flux of an active agent comprising the steps of administering to a nail the topical formulation of claim 36 with a therapeutically effective amount of an active agent.
58 . The method defined in claim 57 , wherein the active agent is selected from the group consisting of an antifungal agent, an anti-inflammatory agent, an anti-cancer agent an antipsoriatic agent and pharmaceutically acceptable salts thereof.
59 . A method of delivering an active agent into or through the nail comprising the steps of administering to a nail a therapeutically effective amount of the nail formulation of claim 1 .